Back

argenx SE

Below you will find information from the register publication of inside information. The information has been provided by the organisation.

  • Registration date 17 sep 2018 - 07:06
  • Statutory name argenx SE
  • Title argenx reports positive topline results from Phase 2 proof-of-concept trial of efgartigimod in primary immune thrombocytopenia

Related downloads

201809170000000003_argenx_EN_17092018.pdf

Date last update: 17 November 2018

Share information

Share on: Share this